Carboplatin-Based High-Dose Therapy for Refractory Acute Myeloid Leukaemia-Reference-Cited by-同舟云学术

Carboplatin-Based High-Dose Therapy for Refractory Acute Myeloid Leukaemia

Published:1998 Issue: Volume: Page:978-985
ISSN:0440-0607
Container-title:Haematology and Blood Transfusion / Hämatologie und Bluttransfusion
language:
Short-container-title:

Author:

Bassan R.,Lerede T.,Buelli M.,Rossi A.,Rambaldi A.,Borleri G.,Bellavita P.,Comotti B.,Cortelazzo S.,Viero P.,Barbui T.

Publisher

Springer Berlin Heidelberg

Link

http://link.springer.com/content/pdf/10.1007/978-3-642-71960-8_136.pdf

Reference26 articles.

1. Estey E (1996) Treatment of refractory AML. Leukemia 10: 932–936

2. Hiddemann W, Martin WR, Sauerland CM, Hei-necke A, Buchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 4: 184–188

3. Keating MJ, Cork A, Broach Y et al. (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res 11: 119–133

4. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ (1994) Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 81 (Suppl 1): 111a

5. to Boekhorst P, Löwenberg B, van Kapel J, Noo-ter K, Sonneveld P (1995) Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 9: 1025–1031

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous-Infusion Carboplatin in Combination with Idarubicin or Mitoxantrone for High-Risk Acute Myeloid Leukemia: A Randomised Phase II Study;Leukemia & Lymphoma;1999-01